Prediction of dexamethasone release from PLGA microspheres prepared with polymer blends using a design of experiment approach.

Hydrophobic drug release from poly (lactic-co-glycolic acid) (PLGA) microspheres typically exhibits a tri-phasic profile with a burst release phase followed by a lag phase and a secondary release phase. High burst release can be associated with adverse effects and the efficacy of the formulation cannot be ensured during a long lag phase. Accordingly, the development of a long-acting microsphere product requires optimization of all drug release phases. The purpose of the current study was to investigate whether a blend of low and high molecular weight polymers can be used to reduce the burst release and eliminate/minimize the lag phase. A single emulsion solvent evaporation method was used to prepare microspheres using blends of two PLGA polymers (PLGA5050 (25 kDa) and PLGA9010 (113 kDa)). A central composite design approach was applied to investigate the effect of formulation composition on dexamethasone release from these microspheres. Mathematical models obtained from this design of experiments study were utilized to generate a design space with maximized microsphere drug loading and reduced burst release. Specifically, a drug loading close to 15% can be achieved and a burst release less than 10% when a composition of 80% PLGA9010 and 90 mg of dexamethasone is used. In order to better describe the lag phase, a heat map was generated based on dexamethasone release from the PLGA microsphere/PVA hydrogel composite coatings. Using the heat map an optimized formulation with minimum lag phase was selected. The microspheres were also characterized for particle size/size distribution, thermal properties and morphology. The particle size was demonstrated to be related to the polymer concentration and the ratio of the two polymers but not to the dexamethasone concentration.

[1]  Fotios Papadimitrakopoulos,et al.  Controlling Acute Inflammation with Fast Releasing Dexamethasone-PLGA Microsphere/PVA Hydrogel Composites for Implantable Devices , 2007, Journal of diabetes science and technology.

[2]  Diane J Burgess,et al.  Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Diane J Burgess,et al.  A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. , 2011, International journal of pharmaceutics.

[4]  Lutz Heinemann,et al.  Current Trends in Continuous Glucose Monitoring , 2014, Journal of diabetes science and technology.

[5]  M. Davies,et al.  Influence of formulation composition and process on the characteristics and in vitro release from PLGA-based sustained release injectables. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[6]  Robert Langer,et al.  Preparation of monodisperse biodegradable polymer microparticles using a microfluidic flow-focusing device for controlled drug delivery. , 2009, Small.

[7]  M. Fowler Microvascular and Macrovascular Complications of Diabetes , 2008, Clinical Diabetes.

[8]  T. Burke,et al.  Stabilization of 10-Hydroxycamptothecin in Poly(lactide-co-glycolide) Microsphere Delivery Vehicles , 1997, Pharmaceutical Research.

[9]  D. Burgess,et al.  Microspheres Prepared with PLGA Blends for Delivery of Dexamethasone for Implantable Medical Devices , 2013, Pharmaceutical Research.

[10]  Yan Wang,et al.  Polymeric "smart" coatings to prevent foreign body response to implantable biosensors. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Fotios Papadimitrakopoulos,et al.  PLGA/PVA hydrogel composites for long-term inflammation control following s.c. implantation. , 2010, International journal of pharmaceutics.

[12]  N. Peppas,et al.  A simple equation for the description of solute release. III. Coupling of diffusion and relaxation , 1989 .

[13]  Fotios Papadimitrakopoulos,et al.  Biomaterials/Tissue Interactions: Possible Solutions to Overcome Foreign Body Response , 2010, The AAPS Journal.

[14]  Kinam Park,et al.  Control of encapsulation efficiency and initial burst in polymeric microparticle systems , 2004, Archives of pharmacal research.

[15]  P. Deluca,et al.  Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  Diane J Burgess,et al.  A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. , 2012, International journal of pharmaceutics.

[17]  S. Allison Analysis of initial burst in PLGA microparticles , 2008 .

[18]  F. Papadimitrakopoulos,et al.  Prevention of foreign body reaction in a pre-clinical large animal model. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[19]  F. Papadimitrakopoulos,et al.  Dexamethasone-loaded poly(lactic-co-glycolic) acid microspheres/poly(vinyl alcohol) hydrogel composite coatings for inflammation control. , 2004, Diabetes technology & therapeutics.

[20]  T. Henning Commercially Available Continuous Glucose Monitoring Systems , 2009 .

[21]  Pauline E. Leary,et al.  Elevated temperature accelerated release testing of PLGA microspheres. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Diane J. Burgess,et al.  Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Hirenkumar K. Makadia,et al.  Poly Lactic-co-Glycolic Acid ( PLGA ) as Biodegradable Controlled Drug Delivery Carrier , 2011 .

[24]  J. Siepmann,et al.  Effect of the size of biodegradable microparticles on drug release: experiment and theory. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[25]  S Kumar,et al.  Formulation parameters of crystalline nanosuspensions on spray drying processing: a DoE approach. , 2014, International journal of pharmaceutics.

[26]  J. Siepmann,et al.  Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). , 2001 .

[27]  A. Mitra,et al.  Effect of Polymer Blending on the Release of Ganciclovir from PLGA Microspheres , 2006, Pharmaceutical Research.

[28]  Fotios Papadimitrakopoulos,et al.  Controlled release of dexamethasone from PLGA microspheres embedded within polyacid-containing PVA hydrogels , 2005, The AAPS Journal.

[29]  Antonio P. Costa,et al.  Application of quality by design to formulation and processing of protein liposomes. , 2012, International journal of pharmaceutics.

[30]  Lisa Samuelson,et al.  Recent Developments in Less Invasive Technology to Monitor Blood Glucose Levels in Patients with Diabetes , 2009 .

[31]  Santhisagar Vaddiraju,et al.  Technologies for Continuous Glucose Monitoring: Current Problems and Future Promises , 2010, Journal of diabetes science and technology.

[32]  Bing Gu,et al.  Optimization of the Büchi B-90 spray drying process using central composite design for preparation of solid dispersions. , 2015, International journal of pharmaceutics.